About the Acute Lymphoblastic Leukemia Session
Acute Lymphoblastic Leukemia (ALL) is a fast-progressing cancer of the blood and bone marrow, primarily affecting children but also occurring in adults. Recent advances in cancer research have significantly improved the understanding and treatment of ALL. Innovative therapies, such as chimeric antigen receptor (CAR) T-cell therapy, have shown promise in targeting and eradicating leukemic cells with precision. Additionally, advancements in genetic profiling and molecular diagnostics have enabled personalized treatment approaches, increasing remission rates and reducing relapse. Ongoing clinical trials are exploring novel drug combinations and immunotherapies to enhance patient outcomes further. As research continues, the goal is to develop more effective, less toxic treatments, offering hope for improved survival and quality of life for ALL patients.
Topics Covered in Acute Lymphoblastic Leukemia
B-Cell & T-Cell Subtypes
BCR-ABL Positive Disease
MRD-Guided Therapy
CAR-T Cell Therapy
Bispecific Antibodies
CNS Prophylaxis
Related Scientific Sessions at CIOC 2027
Why Attend the Acute Lymphoblastic Leukemia Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Acute Lymphoblastic Leukemia work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Acute Lymphoblastic Leukemia research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Acute Lymphoblastic Leukemia track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Acute Lymphoblastic Leukemia Conference 2027 — FAQs
What is the Acute Lymphoblastic Leukemia track at CIOC 2027?
The Acute Lymphoblastic Leukemia track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Acute Lymphoblastic Leukemia. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Acute Lymphoblastic Leukemia sessions?
Cancer researchers and clinicians, educators and students with an interest in Acute Lymphoblastic Leukemia are all welcome — whether presenting or attending.
Can I present my research in the Acute Lymphoblastic Leukemia track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Acute Lymphoblastic Leukemia sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Acute Lymphoblastic Leukemia track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.